A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

Phase 1 Recruiting 44 enrolled Beijing GoBroad Hospital Overland Therapeutics · collab

NaSingle-groupOpen-labelTreatment

Summary

This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-CD19-GDT in relapsed/refractory autoimmune diseases.

Timeline

Start: 2025-10
Primary completion: 2027-12
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OL-CD19-GDT	Cell therapy	—	Intravenous

A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

Summary

Timeline

Drugs

Indications